Third Harmonic Bio down on discontinuation of inflammation drug study

Third Harmonic Bio

15/12/2022 12:56

** Shares of Third Harmonic Bio Inc  THRD.O  slides 55% at
$8.91 premarket
    ** Co said it will discontinue the ongoing early-stage study
of its experimental drug to treat patients with severe allergy
and inflammation citing safety concerns  urn:newsml:reuters.com:*:nGNXc0CXYS
    ** Two of the subjects enrolled in the study were observed
with asymptomatic increase in liver enzymes which can lead to
liver disorder 
    ** Co plans to provide an update on overall corporate
strategy and outlook in early 2023
    ** Up to Wednesday's close, stock had risen ~18% since debut
in Sept. 15
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))